- Home
- GNLX vs TIL Comparison
GNLX vs TIL Comparison
Compare GNLX & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNLX | TIL |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.6M | 54.8M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GNLX | TIL |
|---|---|---|
| Price | $2.88 | $8.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | $17.25 | ★ $125.00 |
| AVG Volume (30 Days) | ★ 155.2K | 27.8K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.47 | 6.06 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.29 | $5.67 |
| 52 Week High | $8.54 | $42.75 |
Technical Indicators
Market Signals| Indicator | GNLX | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 53.83 | 51.12 |
| Support Level | $2.39 | $8.07 |
| Resistance Level | $2.97 | $8.30 |
| Average True Range (ATR) | 0.22 | 0.23 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 37.04 | 78.74 |
Price Performance
Historical ComparisonAbout GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.